Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A with functional gait training for Parkinson's disease foot dystonia
NL-OMON51253Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of botulinum toxin type A in Parkinson's disease (PD) and dystonia (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Canadian Occupational Performance Measure personal goal evaluation. Planned start Oct 2021; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
Parkinson's disease (PD)dystonia
Beyond the preview
Go deeper on NL-OMON51253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51253.